{"TopicDetails": {"type": 0, "ccm2Id": 46015116, "cftId": 0, "identifier": "HORIZON-JU-GH-EDCTP3-2023-01-01", "title": "Global Health EDCTP3 Training Networks - Clinical Research Fellowships", "publicationDateLong": 1681430400000, "callIdentifier": "HORIZON-JU-GH-EDCTP3-2023-01", "callTitle": "HORIZON-JU-GH-EDCTP3-2023-01", "callccm2Id": 46015337, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["clinical research capacity", "clinical trials", "edctp", "Africa", "sub-Saharan Africa", "clinical research", "edctp3", "health", "training", "neglected infectious diseases", "global health", "infectious diseases", "fellowships"], "keywords": ["Infectious diseases", "Social sciences and humanities", "Clinical research", "Public health", "International Cooperation", "Clinical trials", "Societal Engagement", "Global health", "Africa"], "flags": ["SSH", "EC-WORLD", "SocietalEngagement", "Africa"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "10 May 2023", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["04 July 2023"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3484194": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-03 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 26000000}, "expectedGrants": 6, "minContribution": 4000000, "maxContribution": 4000000, "budgetTopicActionMap": {}}], "3484196": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-02 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 14000000}, "expectedGrants": 12, "minContribution": 200000, "maxContribution": 2500000, "budgetTopicActionMap": {}}], "3484198": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-04 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 11000000}, "expectedGrants": 4, "minContribution": 3000000, "maxContribution": 3000000, "budgetTopicActionMap": {}}], "3484200": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-05 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 8000000}, "expectedGrants": 8, "minContribution": 1000000, "maxContribution": 1000000, "budgetTopicActionMap": {}}], "3484202": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-01 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 15300000}, "expectedGrants": 3, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2023"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>Project results are expected to contribute to the following outcomes:</p><ul level=\"0\"><li>Provide answers to research questions in the area of infectious disease clinical research of relevance for SSA and especially in the countries most severely affected by infectious diseases;</li><li>Contribute to generate plausible solutions to improve uptake of innovations and new medical products;</li><li>Increase the number of skilled infectious disease personnel working in SSA;</li><li>Promote the career development and retention of skilled personnel in SSA;</li><li>Strengthen the SSA countries\u2019 clinical human capital base in Research and Innovation (R&amp;I);</li><li>Enhance talent retention and knowledge circulation and uptake across the SSA R&amp;I landscape;</li><li>Improve the attractiveness of infectious disease clinical research careers in SSA;</li><li>Contribute to the generation of a critical mass of clinicians and institutional clinical research capacity in SSA;</li><li>Enhance clinical research capacity in poverty-related diseases, especially in the countries with the highest infectious disease burden;</li><li>Enhance the application of One Health approaches across SSA;</li><li>Strengthen the ability of SSA countries to prepare for and to manage epidemic disease outbreaks;</li><li>Encourage cooperation between researchers and clinicians in SSA with Africa CDC<sup>[1]</sup>, African Union Development Agency New Partnership for Africa's Development AUDA-NEPAD<sup>[2]</sup>, World Health Organization African Region (WHO-Afro)<sup>[3]</sup>, African Vaccine Regulatory Forum AVAREF<sup>[4]</sup> and other organisations relevant for R&amp;I;</li><li>Establish sustainable and mutually beneficial collaboration between clinical research organisations within SSA and Europe;</li><li>Foster a culture of collaboration with Global Health EDCTP3 like-minded funders working in SSA;</li><li>Foster a culture of open science, innovation, and entrepreneurship in SSA;</li><li>Improve equity in research between the genders and across anglophone, francophone and lusophone sub-Saharan Africa.</li> </ul><p><sup>[1]</sup>African Union Africa CDC Centres for Disease Control and Prevention <a href=\"https://africacdc.org/\">https://africacdc.org/</a></p><p><sup>[2]</sup><a href=\"https://www.nepad.org/\">https://www.nepad.org/</a></p><p><sup>[3]</sup><a href=\"https://www.afro.who.int/\">https://www.afro.who.int/</a></p><p><sup>[4]</sup><a href=\"https://www.afro.who.int/health-topics/immunization/avaref\">https://www.afro.who.int/health-topics/immunization/avaref</a></p>\n<SPAN class=\"topicdescriptionkind\">Objective</SPAN>:<p>The Global Health EDCTP3 Training Networks aim to train and develop skilled, innovative, and resilient African researchers, scientists, clinicians, and other public health professionals working in the area of infectious disease research. The main objective is that these professionals can face current and future clinical research challenges, efficiently carry out clinical trials, mentor young scientists, implement research results, apply knowledge into development of products and services and/or analyse data to inform policy and practice for better health for all in sub-Saharan Africa (SSA). Through the training being offered to the fellows, important research questions within the framework of the Strategic Research and Innovation Agenda of Global Health EDCTP3<sup>[1]</sup> will be addressed.</p><p>The Global Health EDCTP3 Training Networks will strengthen the clinical research capacity and attractiveness of clinical research in SSA countries. They will equip health research professionals with the right combination of research-related competences and capabilities to enhance their career perspectives.</p><p><sup>[1]</sup><a href=\"http://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf\">https://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf</a></p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The Global Health EDCTP3 Training Networks will implement training programmes through consortia of clinical research institutions, academia, industry, businesses (including SMEs) and other socio-economic actors from different countries across SSA and Europe, with the objective to strengthen the health research systems of the SSA countries with the highest disease burden. Proposals should include training programmes for researchers, scientists, clinicians and/or other public health professionals in the area of infectious disease research, with practical field research experience. The individuals being trained will carry out ambitious and relevant clinical research projects on infectious diseases affecting SSA.</p><p>Global Health EDCTP3 Training Networks proposals should be submitted by a consortium of institutions which must provide training through research programmes to early- to mid-career researchers based in SSA. The fellows must commit to be in Africa for a minimum of two years after completing their training and provide evidence to demonstrate this through a letter of support from their host institution(s).</p><p>Proposals should include institutions with a proven track record in the provision of high-quality research training and established regional and global collaborations. These may include research organisations, institutions of higher learning such as universities, national public health institutes or similar agencies, research councils, or other relevant institutions or government ministries. Proposals may also include industry, businesses (including SMEs) and other socio-economic actors.</p><p>These consortia should respond to well-identified needs on infectious disease research and innovation in SSA and describe the transfer of knowledge towards the countries with higher disease burden<sup>[1]</sup>, ensuring that the benefit of the training goes to less-experienced institutions/countries. South-South collaboration is strongly encouraged, although North-South collaboration is not excluded. Where appropriate, the training programmes should expose the fellows to collaboration with national departments of health as well as with international and regional organisations<sup>[2]</sup>.</p><p>The consortia should also offer transferable skills and competences relevant for innovation and fellows\u2019 long-term employability, including financial administration, communication, commercialisation of results, entrepreneurship, intellectual property rights, etc.</p><p>The maximum duration of a training programme of a Global Health EDCTP3 Training Network should be 54 months.</p><p>The training programme should include two levels of fellows to be trained by experienced researchers, where the higher level provides training and mentorship for the lower one:</p><p>- <strong>Early-Stage Career Fellowships</strong> to support researchers and other members of clinical research teams from SSA to acquire specific skills in clinical research through placements in pharmaceutical companies, contract research organisations (CROs), clinical or academic affiliated research organisations and/or product development partnerships (PDPs). This category covers both hands-on-training apprenticeship and Master and PhD training arrangements where the candidates can spend part of their training and supervision at a more established or complementary institution with skill sets, expertise and or competences not available at the fellows' host African institution(s).</p><p>Target individuals should meet all the following criteria:<strong> </strong></p><ol level=\"0\">  <li>Citizens or residents from a SSA country with a higher infectious disease burden than the country of the host organisation;</li><li>Exceptionally, be citizens from non-SSA country willing to relocate to a SSA country with higher infectious disease burden;</li><li>Preference to citizens or residents from a SSA low-income countries with lower clinical research capacity<sup>[3]</sup>;</li><li>Be either postgraduate MD, MSc, or PhD candidate, in an area relevant to infectious diseases or clinical staff with experience in infectious diseases employed for the last 12 months in an organisation with a registered legal entity in SSA;</li> </ol><p>Duration of a single fellowship: between a minimum of 6 and a maximum of 36 months with the possibility of secondments up to a third of the single fellowship duration.</p><p>Expected minimum number of Early-Stage Career fellowships per proposal: 4, expected maximum number of Early-Stage Career fellowships per proposal: 10.</p><p>- <strong>Mid-Career Fellowships</strong> to support researchers and key members of clinical research teams from SSA in their mid-career to develop their clinical research skills. The objective is to promote career development and retention of post-doctoral clinical researchers in SSA, to equip the fellows with the ability to establish themselves as independent researchers and with the skills to initiate and manage their own research at host organisations in the SSA countries with the highest disease burden.</p><p>Target individuals should meet all the following criteria:</p><ol level=\"0\">  <li>Be citizens or residents from a SSA country with higher infectious disease burden;</li><li>Exceptionally, be citizens from non-SSA country willing to relocate to a SSA country with higher infectious disease burden;</li><li>Preference to citizens or residents from a SSA low-income country with lower clinical research capacity<sup>20</sup>;</li><li>MD/PhD related to infectious diseases or clinical research or a medical graduate with at least five years\u2019 relevant research experience;</li><li>At least one publication in an international peer-reviewed journal.</li> </ol><p>Duration of a single fellowship: between a minimum of 6 and a maximum of 24 months and can have secondments up to a third of the fellowship duration.</p><p>Expected minimum number of Mid-Career fellowships per proposal: 2, expected maximum number of Mid-Career fellowships per proposal: 5.</p><p>The two training levels must be well integrated and designed to provide the required training support for the fellows. Training programmes should develop different training modules, including digital ones, addressing key transferable skills and competences common to all fields of clinical research, including research management and financial aspects, research collaboration and information-sharing, made possible by (digital) technologies (e.g. collaborative tools, opening access to publications and to other research outputs including data, FAIR data management, societal engagement and citizen science, etc.), and fostering the culture of Open Science, innovation and entrepreneurship as well as good scientific conduct such as research integrity.</p><p>Training programmes should have regular selection rounds following fixed deadlines or regular cut-off dates, allowing fair competition between candidates. The selection procedure for candidates must be open, transparent, and merit-based, in line with the Code of Conduct for the Recruitment of Researchers<sup>[4]</sup>. The vacancy notices should be widely advertised in SSA countries and include the gross salary to be offered to the fellows (not including employer\u2019s social contributions). The selection of the fellows should address gender and language/regional equity barriers.</p><p>Proposals must demonstrate the following:</p><ul level=\"0\"><li>A high-quality training programme related to clinical research or implementation research on infectious diseases of importance in SSA, including One Health;</li><li>An open, fair, and transparent procedure for selecting the fellows coming from different geographical regions of SSA, based on quality and with appropriate gender balance, with an active open promotion of the vacancies specifically addressed to female candidates, as well as to candidates from French speaking and Portuguese speaking countries to ensure that candidates from these groups can be well represented;</li><li>Robust mentorship mechanisms to support the fellows through their training period up to completion;</li><li>A robust monitoring and evaluation mechanism used to assess the career progression of the fellows, the impact of the training programme in the region and compile lessons learnt that can be used to inform future training programmes;</li><li>The training programme must be conducted in SSA, in collaboration with relevant local or regional organisations such as National Public Health Institutes (and/or similar agencies), Ministries of Health, Research Councils and other relevant institutions;</li><li>Whenever relevant, training programmes should expose fellows to collaboration with regional and international organisations, e.g., Africa CDC, AUDA-NEPAD, WHO-Afro, AVAREF and/or other organisations relevant for R&amp;I;</li><li>Training programmes should be designed with different training modules addressing also key transferable skills and competences concerning clinical research management including communication, ethical, regulatory, administrative, and financial aspects;</li><li>Training programmes should include individual fellows training packages so that the fellows can deliver on their individual expected results;</li><li>Proposals should also include support for meetings and conferences for the trainees to participate in the annual networking meetings, conferences and forums organised by relevant African organisations such as Africa CDC, EDCTP, WHO-Afro, AUDA-NEPAD, and other relevant events;</li><li>Linkages with other EDCTP actions should be foreseen (e.g., EDCTP Networks of Excellence<sup>[5]</sup> or Alumni Network<sup>[6]</sup>).</li><li>Capacity to provide adequate training on skills and competences relevant for innovation, e.g., entrepreneurship, commercialisation of results, intellectual property rights, etc.</li> </ul><p>To strengthen the clinical research capacity in the SSA regions with the highest disease burden, expert evaluators will be asked to take the possibility/likelihood of the transfer of knowledge particularly into account when evaluating the \u2018impact\u2019 criterion of the proposal<em>.</em></p><p>Financial contributions from EDCTP-Association and third parties (e.g., foundations) interested in this scheme are encouraged to contribute to increase the budget, diversity, and impact.</p><p><strong>Contributions for recruited researchers and institutions per person-month</strong></p><p>Monthly contributions are based on the Marie Sk\u0142odowska Curie schemes (MSCA) contributions. To the living allowance a country correction coefficient<sup>[7]</sup> for the recruited researcher will be applied to ensure equal treatment and purchasing power parity for all fellows. The mobility allowance will cover additional, private mobility-related costs (e.g., travel and accommodation costs), but not travel for professional or research purposes. A family allowance will contribute to mobility-related costs of researchers with family obligations which can be granted during the project.</p><p><strong>Early-Stage Career (taken from the MCSA Work Programme 2023-2024 Doctoral Fellowships)</strong></p><table>  <tbody>   <tr>    <td rowspan=\"3\"> <p><strong>MSCA</strong></p> <p><strong>Doctoral</strong></p> <p><strong>Networks</strong></p> </td>    <td colspan=\"5\"> <p><strong>Contributions for recruited researchers</strong></p> <p><strong>per person-month</strong></p> </td>    <td colspan=\"2\"> <p><strong>Institutional unit contributions per person-month</strong></p> </td>   </tr>   <tr>    <td> <p><strong>Living allowance</strong></p> </td>    <td> <p><strong>Mobility allowance</strong></p> </td>    <td> <p><strong>Family allowance </strong>(if applicable)</p> </td>    <td> <p><strong>Long-term leave allowance </strong>(if applicable)</p> </td>    <td> <p><strong>Special needs allowance </strong>(if applicable)</p> </td>    <td> <p><strong>Research, training, and networking contribution</strong></p> </td>    <td> <p><strong>Management and indirect contribution</strong></p> </td>   </tr>   <tr>    <td> <p> </p> <p> </p> <p>EUR 3 400</p> <p> </p> </td>    <td> <p> </p> <p> </p> <p>EUR 600</p> </td>    <td> <p> </p> <p> </p> <p>EUR 660</p> </td>    <td> <p>EUR 4 000</p> <p>x % covered by the beneficiary</p> </td>    <td> <p>Requested unit</p> <p>x (1/number of months)</p> </td>    <td> <p> </p> <p> </p> <p>EUR 1 600</p> </td>    <td> <p> </p> <p> </p> <p>EUR 1 200</p> </td>   </tr>  </tbody> </table><p><strong>Mid-Term Development Career (taken from the MSCA Work Programme 2023-2024 Postdoctoral Fellowships)</strong></p><table>  <tbody>   <tr>    <td rowspan=\"3\"> <p><strong>MSCA</strong></p> <p><strong>Postdoctoral</strong></p> <p><strong>Fellowships</strong></p> </td>    <td colspan=\"5\"> <p><strong>Contributions for the recruited researcher</strong></p> <p><strong>per person-month</strong></p> </td>    <td colspan=\"2\"> <p><strong>Institutional unit contributions </strong></p> <p><strong>per person-month</strong></p> </td>   </tr>   <tr>    <td> <p><strong>Living allowance</strong></p> </td>    <td> <p><strong>Mobility allowance</strong></p> </td>    <td> <p><strong>Family allowance </strong>(if applicable)</p> </td>    <td> <p><strong>Long-term leave allowance </strong>(if applicable)</p> </td>    <td> <p><strong>Special needs allowance </strong>(if applicable)</p> </td>    <td> <p><strong>Research, training, and networking contribution</strong></p> </td>    <td> <p><strong>Management and indirect contribution</strong></p> </td>   </tr>   <tr>    <td> <p> </p> <p> </p> <p>EUR 5 080</p> <p> </p> </td>    <td> <p> </p> <p> </p> <p>EUR 600</p> </td>    <td> <p> </p> <p> </p> <p>EUR 660</p> </td>    <td> <p>EUR 5680</p> <p>x % covered by the beneficiary</p> </td>    <td> <p>Requested unit</p> <p>x (1/number of months)</p> </td>    <td> <p> </p> <p> </p> <p>EUR 1 000</p> </td>    <td> <p> </p> <p> </p> <p>EUR 650</p> </td>   </tr>  </tbody> </table><p><sup>[1]</sup><a href=\"http://www.who.int/data/gho/data/countries\">https://www.who.int/data/gho/data/countries</a></p><p><sup>[2]</sup>International and regional organisations mentioned above</p><p><sup>[3]</sup>See Figure 4 \u2013 Scatter plot - severity/urgency of need vs relative research capacity \u2013 low-income countries at <a href=\"http://tdr.who.int/docs/librariesprovider10/essence/essence-mechanism-consultant-report-2020.pdf\">https://tdr.who.int/docs/librariesprovider10/essence/essence-mechanism-consultant-report-2020.pdf</a></p><p><sup>[4]</sup><a href=\"http://euraxess.ec.europa.eu/jobs/charter\">https://euraxess.ec.europa.eu/jobs/charter</a></p><p><sup>[5]</sup><a href=\"http://www.edctp.org/our-work/edctp-regional-networks-of-excellence/\">http://www.edctp.org/our-work/edctp-regional-networks-of-excellence/</a></p><p><sup>[6]</sup><a href=\"http://www.edctp.org/our-work/fellowship-programme/edctp-alumni-network/\">http://www.edctp.org/our-work/fellowship-programme/edctp-alumni-network/</a></p><p><sup>[7]</sup><a href=\"http://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-2-msca-actions_horizon-2023-2024_en.pdf\">https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-2-msca-actions_horizon-2023-2024_en.pdf</a></p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p><u>Expected impacts of the calls under the 2023 work programme of the Global Health EDCTP3 JU</u></p><p>Activities funded under the 2023 calls for proposals should contribute to:</p><ul level=\"0\"><li>Achieve SDG3 \u2018Ensure healthy lives and promote well-being for all at all ages\u2019 in sub-Saharan African countries;</li><li>Enable the implementation of the short and medium term actions foreseen by the AU EU Innovation Agenda<sup>[1] </sup>(expected to be adopted in June 2023) in the area of Public Health</li><li>Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;</li><li>Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;</li><li>Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;</li><li>Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;</li><li>Strengthen health systems to ensure uptake of effective health technologies and innovations;</li><li>Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.</li><li>Improve opportunities for training of researchers and healthcare professionals in sub-Saharan Africa.</li> </ul><p><sup>[1]</sup>Working document of the AU EU Innovation Agenda available online at: <a href=\"http://research-and-innovation.ec.europa.eu/system/files/2022-02/final_au-eu_ia_14_february.pdf\">https://research-and-innovation.ec.europa.eu/system/files/2022-02/final_au-eu_ia_14_february.pdf</a></p>\n", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes</span></span></span></p>\n<p style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b></span></span></span></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">The conditions are described in General Annex B except for the specific conditions for GH EDCTP3 funding as regards&nbsp;<u>Entities eligible for funding</u>&nbsp;and&nbsp;<u>Consortium composition,</u>&nbsp;the specific issue of&nbsp;<u>legal entities from which countries can be the coordinator</u>&nbsp;and the obligation to designate a&nbsp;<u>scientific project leader</u>. Participation conditions related to Russia&rsquo;s illegal invasion of Ukraine are also set out below.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><u>Replacing relevant sections in General Annex B to the Horizon Europe work programmes on Eligibility</u></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><em><u>Entities eligible to participate</u></em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, the currently context does not allow the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine. Therefore, such legal entities are not eligible to participate in any capacity. This criterion also applies in cases where the action involves financial support given by grant beneficiaries to third parties established in Russia, Belarus or in non-government-controlled territories of Ukraine (in accordance with Article 204 of the Financial Regulation No 2018/1046).</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">To be eligible for funding, applicants must be established in one of the following countries:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;</li>\r\n    <li>The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Cura&ccedil;&atilde;o (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barth&eacute;lemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);</li>\r\n    <li>Countries associated to Horizon Europe<sup>[1]</sup>; Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo<sup>[2]</sup>, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine. Considering the Union&rsquo;s interest to retain, in principle, relations with the countries associated to Horizon 2020, most third countries associated to Horizon 2020 are expected to be associated to Horizon Europe with an intention to secure uninterrupted continuity between Horizon 2020 and Horizon Europe. In addition, other third countries can also become associated to Horizon Europe during the programme. For the purposes of the eligibility conditions, applicants established in Horizon 2020 Associated Countries or in other third countries negotiating association to Horizon Europe will be treated as entities established in an Associated Country, if the Horizon Europe association agreement with the third country concerned applies at the time of signature of the grant agreement<sup>[3]</sup>;</li>\r\n    <li>The following low- and middle-income countries which are constituent states of the EDCTP Association<sup>[4]</sup>: Burkina Faso, Cameroon, Congo, C&ocirc;te d&rsquo;Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call conditions, or if their participation is considered essential for implementing the action by the granting authority.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Consortium composition</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the GH EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>At least three legal entities established in different countries, where legal entities are eligible to receive funding;</li>\r\n    <li>At least one independent legal entity established in a Member State or an associated country; and</li>\r\n    <li>At least one independent legal entity established in a sub-Saharan African (SSA) country that is a member of the EDCTP Association.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><em>Specific cases:</em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong>Affiliated entities</strong>&nbsp;&ndash; Affiliated entities are eligible for funding if they are established in one of the countries listed above.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong>International organisations</strong>&nbsp;&ndash; International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Specific rules on which legal entities can be the coordinator of an indirect action</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">According to article 110 of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe<sup>[5]</sup>, where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the financial coordinator of the indirect action shall be established in a Member State or associated country. Of the SSA countries members of the EDCTP Association, only South Africa concluded such an agreement.<sup>[6]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Scientific project leader</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">If the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on &lsquo;scientific project leadership&rsquo; must be included in the proposals and budget needs to be provided for this activity.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;</li>\r\n    <li>Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;</li>\r\n    <li>Act as the key contact point for the GH EDCTP3 regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, acting as the key contact point for the GH EDCTP3 JU for these matters including external communication, other than the ones entrusted directly to the coordinator as per the Model Grant Agreement;</li>\r\n    <li>Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;</li>\r\n    <li>Review the action&rsquo;s deliverables and reports before their submission by the coordinator;</li>\r\n    <li>Lead the work packages(s) related to the tasks of scientific project leadership.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to the GH EDCTP3 JU on all issues of interest for the proper scientific management of the action.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[1]</sup>The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding &amp; Tenders Portal for up-to-date information on the current list and on the position for Associated Countries.&nbsp;<a href=\"http://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf\" style=\"color: rgb(51, 51, 51);\">https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[2]</sup>This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[3]</sup>Association of New Zealand is expected to take effect during 2023.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[4]</sup>The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website&nbsp;<a href=\"http://www.edctp.org/\" style=\"color: rgb(51, 51, 51);\">www.edctp.org</a>.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[5]</sup>Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014.&nbsp;<em>OJ L 427, 30.11.2021, p. 17&ndash;119; https://eur-lex.europa.eu/eli/reg/2021/2085</em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[6]</sup><a href=\"http://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/europe-world/international-cooperation/south-africa_en\" style=\"color: rgb(51, 51, 51);\">https://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/europe-world/international-cooperation/south-africa_en</a></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><strong><u>Replacing relevant section in General Annex D to the Horizon Europe work programmes</u></strong></p><p><strong><em><u>Scores and weighting</u></em></strong></p><p>Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.</p><p>Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span></p>\r\n<p>&nbsp;</p>\n<p>Beneficiaries may provide financial support to third parties. The support to third parties can only be provided in the form of grants. The maximum amount to be granted to each third party is EUR 300 000. This is justified since the main objective of these projects is to provide fellowship support.The relevant options of the Model Grant Agreement will apply.</p>\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">Specific conditions</span></b></span></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme</span></span></span></span></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><b>Scientific Project Leader</b></span></font></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">For all projects under this topic, if the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described in the introduction is mandatory. A work package on &lsquo;scientific project leadership&rsquo; must be included in the proposals and budget needs to be provided for this activity.</span></font><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><br />\r\n</span></font></p>\r\n<p class=\"MsoNormal\"><strong><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">Grant Conditions - EC objection to transfer of ownership to a third party in a third country</span></font></strong></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">According to the Horizon Europe rules, and to protect Union interests, the right for the GH EDCTP3 to object to transfers of ownership of results or to grants of an exclusive licence regarding results should apply to participants. Therefore, the provisions set out in General Annex G to the Horizon Europe work programmes on the right to object apply generally. It should be noted that in accordance with the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[1] and the Model Grant Agreement, the right to object applies also to participants that have not received funding from the JU and for the periods set therein.</span></font><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><br />\r\n</span></font></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17</span></font></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p></o:p></span></p>\n<h1><span style=\"font-size: medium;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\"><span style=\"font-family: Arial;\">Documents</span></span></b></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><b><span lang=\"EN-US\">Call documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">Standard application form</span></span><span style=\"color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i></span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard application form (HE RIA, IA)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form</span></span><span style=\"font-size: small; color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i> will be used with the necessary adaptations</i></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-ria-ia_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form (HE RIA, IA)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\">MGA</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\">HE <span lang=\"EN-US\">General MGA v1.0</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color: rgb(64, 64, 64); font-size: small;\">Call-specific instructions</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-financial-support-to-third-parties_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on financial support to third parties (HE)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on clinical studies (HE)</span></span></a></span></p>\n<h2><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span></h2>\r\n<h2 style=\"margin-top:0cm\"><b><span lang=\"EN-US\"><o:p></o:p></span></b></h2>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/43297f62-5b31-4375-a54a-a5d3f1b52f44_en?filename=edctp_work_programme_2023.pdf\" target=\"_blank\">Work Programme 2023</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/096afd45-ee04-4aff-9325-138ae37eaa39_en?filename=edctp_wp2023-annex1_calls_for_proposals.pdf\" target=\"_blank\">Annex 1 - Calls for proposals</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/deb9e2bb-a8ab-48dd-b026-fc0fd4f6626b_en?filename=edctp_wp2023_annex_2_ikaa_plan.pdf\" target=\"_blank\">Annex 2 - In-kind contributions (IKAA plan)</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-4-health_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 4. Health</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "<p>&nbsp;<span style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">With the 2023 work programme we extend the range of topics addressed under the GH EDCTP3 JU, building on the activities launched in 2022. The work programme this year puts particular emphasis on capacity building and training. A topic calling for training networks is included (HORIZON-JU-GH-EDCTP3-2023-01-01). Also, for the other topics in the work programme, where relevant, support of African scientists through degree training in clinical research and/or hands on training during implementation of research projects should be provided to assist them in advancing their scientific careers. These scientists should be selected keeping gender balance in mind.</span></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">In the context of this work programme, a clinical study covers clinical studies/trials/investigations/ cohorts and is defined as any systematic prospective or retrospective collection and analysis of health data obtained from individual patients or healthy persons to address scientific questions related to the understanding, prevention, diagnosis, monitoring or treatment of a disease, mental illness, or physical condition. It includes but it is not limited to clinical studies as defined by Regulation 536/2014 (on medicinal products), clinical investigation and clinical evaluation as defined by Regulation 2017/745 (on medical devices), performance study and performance evaluation as defined by Regulation 2017/746 (on in vitro diagnostic medical devices).</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS). CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data. This follows a one-year transition, during which sponsors could choose whether to apply for a new clinical trial in the EU/EEA in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022.<sup>[2]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">In the context of this work programme, FAIR data are data which meet principles of findability, accessibility, interoperability, and reusability. Data can include exploitation of information and data from European data infrastructures and programmes such as Copernicus, European Space Agency, and the GEO initiative. For further details, see the FAIR principles website<sup>[3]</sup>, the FAIR cookbook<sup>[4]</sup>&nbsp;and the guides for researchers on how to make your data FAIR.<sup>[5]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[1]</sup><a href=\"http://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf\" style=\"color: rgb(51, 51, 51);\">https://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[2]</sup><a href=\"http://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu\" style=\"color: rgb(51, 51, 51);\">https://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[3]</sup><a href=\"http://www.go-fair.org/fair-principles/\" style=\"color: rgb(51, 51, 51);\">https://www.go-fair.org/fair-principles/</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[4]</sup><a href=\"http://faircookbook.elixir-europe.org/content/home.html\" style=\"color: rgb(51, 51, 51);\">https://faircookbook.elixir-europe.org/content/home.html</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[5]</sup><a href=\"http://www.openaire.eu/how-to-make-your-data-fair\" style=\"color: rgb(51, 51, 51);\">https://www.openaire.eu/how-to-make-your-data-fair</a></p>", "latestInfos": [{"approvalDate": "Nov 14, 2023 3:12:10 PM", "lastChangeDate": "Nov 14, 2023 3:12:10 PM", "content": "<p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">EVALUATION RESULTS <o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Call Identifier: HORIZON-JU-GH-EDCTP3-2023-01<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Published: 14/04/2023<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Deadline: 04/07/2023<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Available budget: 74.3 million EUR<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p>&nbsp;</o:p></span></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">The results of the evaluation are as follows<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number proposals submitted: 99<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number ineligible proposals: 8<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of above-threshold: 46<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Total budget requested for above-threshold proposals: 152.8 million EUR<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of Main list: 25<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of Reserve list: 8<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of rejected proposals due to budgetary resources: 13<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of proposal upgraded from Reserve list to Main list: 2<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p>&nbsp;</o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">We recently informed the applicants about the evaluation results for their proposals.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">For questions, please contact us at <a href=\"mailto:EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu\">EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu</a></span></p>\r\n</p>"}, {"approvalDate": "Jul 11, 2023 9:56:24 AM", "lastChangeDate": "Jul 11, 2023 9:56:24 AM", "content": "<p><font color=\"#333333\"><span style=\"font-size: 14px;\">Call Single Stage HORIZON-JU-GH-EDCTP3-2023-01 closed on July 4th, 2023.&nbsp;</span></font></p>\r\n<p class=\"MsoNormal\" style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><font color=\"#333333\"><span style=\"font-size: 14px;\">A total of 99 proposals were submitted.&nbsp;</span></font></p>\r\n<p><font color=\"#333333\"><span style=\"font-size: 14px;\">The breakdown per topic is:</span></font></p>\r\n<ul>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-01: 25 proposals&nbsp;</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-02: 18 proposals</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-03: 28 proposals</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-04: 10 proposals</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-05: 18 proposals</span></font></li>\r\n</ul>\r\n<p class=\"MsoNormal\" style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><font color=\"#333333\"><span style=\"font-size: 14px;\">Evaluation results are expected to be communicated on Friday 24th October 2023 at the earliest.</span></font></p>"}, {"approvalDate": "Jun 28, 2023 10:38:52 AM", "lastChangeDate": "Jun 28, 2023 10:38:52 AM", "content": "<p>The call deadline has been postponed to 04/07/2023</p>"}, {"approvalDate": "Jun 28, 2023 10:27:04 AM", "lastChangeDate": "Jun 28, 2023 10:27:04 AM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2023-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-05(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2023-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-04(HORIZON-JU-RIA)"}, {"approvalDate": "May 10, 2023 12:00:01 AM", "lastChangeDate": "May 10, 2023 12:00:01 AM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2023-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-05(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2023-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-04(HORIZON-JU-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}